A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
Kitty K WongPeter A Kempster

Abstract

This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period. Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05). Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties.

References

Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Nov 26, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Michael P HillHenrik Klitgaard
Feb 6, 2004·European Journal of Pharmacology·Erwan BezardHenrik Klitgaard
Sep 25, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Adrian Handforth, Fredricka C Martin
Mar 30, 2005·Clinical Neuropharmacology·G MecoL Morgante
Jun 14, 2005·Parkinsonism & Related Disorders·Babak Tousi, Thyagarajan Subramanian
Jun 15, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Theresa A ZesiewiczRobert A Hauser
Jun 9, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Sascha HeringJoerg Mueller
Jun 15, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Constance L Smith-HicksHarvey S Singer
Mar 4, 2008·The Journal of Clinical Psychiatry·Scott W WoodsCenk Tek
Nov 26, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzGlenn T Stebbins

❮ Previous
Next ❯

Citations

Aug 26, 2014·Expert Opinion on Emerging Drugs·Amaal Al DakheelSusan H Fox
May 28, 2016·Neurodegenerative Disease Management·Maria Eliza Freitas, Susan H Fox
May 26, 2017·Expert Opinion on Investigational Drugs·Silvia CerriFabio Blandini
Dec 12, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Lorraine V KaliaSusan H Fox
Mar 11, 2018·The Journal of Pharmacology and Experimental Therapeutics·Nicolas VeyresPhilippe Huot
Jan 16, 2013·Pharmacological Reviews·Philippe HuotJonathan M Brotchie
Oct 18, 2019·Expert Opinion on Drug Safety·Valentina LetaAngelo Antonini
Oct 17, 2014·Expert Review of Clinical Pharmacology·Anne-Catherine Vijverman, Susan H Fox
Jul 6, 2013·Experimental Biology and Medicine·Ludivine S Breger, Emma L Lane
Aug 23, 2019·Biomolecules·Claudia CarrariniLaura Bonanni

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.